Global Diabetes Market

Publication Date	June 2009
Publisher	Frost & Sullivan
Product Type	Report
Pages	99
ISBN Number	not applicable
Product Code	FRS01207

Buy this product or for assistance call +44 20 7060 7474

PDF £3,910.00$6504 | €4376

FAX Order above formats by FAX

Summary

Emergence of Novel Drug Classes to Boost Market Growth

Increasing knowledge related to the pathology of diabetes will support the introduction of improved drugs to treat the disease. As healthcare moves towards the ideal of preventive medicine, there are a few companies conducting research on diabetes vaccines. If they succeed, the entire market landscape is bound to undergo instant change.

"Improved therapies and innovative drug delivery techniques are anticpated to revolutionise the global diabetes market by 2015," notes the analyst of this research. "As healthcare moves towards preventive medicine, the search for a cure for diabetes looks promising." The emergence of newer classes of drugs to treat diabetes and their co-morbidities is changing the diabetes market landscape. Long-acting GLP-1 analogs are likely to gain significance and almost match the importance of insulin in the near future. This trend is likely to be beneficial for Type-2 diabetics who have not responded to other oral anti-diabetic agents.

Asian Markets Offer Considerable Growth Potential

The Food and Drug Administration (FDA) has detailed stringent policies for the approval of diabetic drugs. These policies compel lengthier clinical trials, often resulting in the delayed launch of new drugs and increased drug development costs. "The not-so conducive regulatory environment, varying price controls across countries and parallel trading hinders the growth of the global diabetes market," adds the analyst. "In addition, generic competition arising due to patent expiries of major drugs is also restraining market expansion."

Despite these obstacles, the diabetes market is, and will continue to be, a lucrative segment of the healthcare industry. Numerous innovative drugs and drug-delivery devices are currently being researched. Given these are successful, the launch of such drugs and devices will further open up the market and boost revenue generation. "Asian markets, especially India and China, offer tremendous prospects for growth," concludes the analyst. "These markets have large diabetic populations and, with the number of undiagnosed diabetics increasing, lucrative untapped opportunities are emerging for pharmaceutical companies."

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

Insulin
Insulin analogues
Non-insulin anti-diabetic drugs

By Geographic Region:

The U.S.
Europe
Japan
Rest-of-World

Content

1 EXECUTIVE SUMMARY OF THE GLOBAL DIABETES MARKET
- Executive Summary
  - 1. Overview of the Global Diabetes Market
2 RESEARCH METHODOLOGY FOR THE GLOBAL DIABETES MARKET
- Research Methodology
  - 1. Methodology
  - 2. Scope and Objectives
3 MARKET INTRODUCTION
- Introduction
  - 1. Diabetic Demography
  - 2. Diabesity
4 CHALLENGES AND UNMET NEEDS IN THE GLOBAL DIABETES MARKET
- Issues and Challenges
  - 1. Industry Challenges
5 CURRENT TREATMENT OPTIONS IN THE GLOBAL DIABETES MARKET
- Current Therapies
  - 1. Analysis of the Key Current Therapies
6 KEY TRENDS IN THE GLOBAL DIABETES MARKET
- A Snapshot of the Key Global Trends
  - 1. Key Trends and Analysis
7 RESEARCH OF THE GLOBAL DIABETES MARKET
- Analysis of the Global Diabetes Drugs Market
  - 1. Measurements
  - 2. Market Drivers
  - 3. Market Restraints
  - 4. Revenue Forecasts
  - 5. Market Share Analysis
  - 6. Competitive Structure
8 REGIONAL ANALYSIS OF THE GLOBAL DIABETES MARKET
- The U.S. Diabetes Market
  - 1. Market Overview
  - 2. Measurements
  - 3. Revenue Forecasts
- European Diabetes Market
  - 1. Market Overview
  - 2. Measurements
  - 3. Revenue Forecasts
- The Japanese Diabetes Market
  - 1. Market Overview
  - 2. Measurements
  - 3. Revenue Forecasts
- Rest-of-World Diabetes Market
  - 1. Market Overview
  - 2. Measurements
  - 3. Revenue Forecasts
9 EMERGING TREATMENT OPTIONS IN THE GLOBAL DIABETES MARKET
- Emerging Therapies
  - 1. Emerging Therapies and Pipeline Analysis
10 APPENDIX
- Decision Support Database
  - 1. Diabetes Incidence
  - 2. Diabetes Prevalence
  - 3. Prevalence Per cent of Diabetes
  - 4. Government Healthcare Expenditure
  - 5. Private Healthcare Expenditure
List of Figures
- Impact of top three industry challenges in the global diabetes market from 2009 to 2015
- SWOT analysis of the global diabetes market in 2008
- Market drivers ranked in order of impact in the global diabetes market from 2009 to 2015
- Market restraints ranked in order of impact in the global diabetes market from 2009 to 2015
- Revenue forecasts for the global diabetes market from 2005 to 2015
- Per cent of revenues by geographic region in the global diabetes market from 2005 to 2015
- Per cent of revenues by geographic region in the global insulin market from 2005 to 2015
- Per cent of revenues by geographic region in the global non-insulin market from 2005 to 2015
- Competitive structure of the global diabetes market in 2008
- Revenue forecasts of the U.S. diabetes market from 2005 to 2015
- Revenue forecasts of the European diabetes market from 2005 to 2015
- Revenue forecasts of the Japanese diabetes market from 2005 to 2015
- Revenue forecasts of the Rest-of-the-World diabetes market from 2005 to 2015
- Pipeline drugs in research stage and preclinical stages in the global diabetes market in 2008
- Phase-I drugs in pipeline in the global diabetes market in 2008
- Phase-II drugs in pipeline in the global diabetes market in 2008
- Phase-III drugs in pipeline in the global diabetes market in 2008
- Halted pipeline drugs in the global diabetes market in 2008
- New cases of diabetes in '000 worldwide from 2002 to 2012
- Prevalence of diabetes in diabetes in '000 worldwide from 2002 to 2012
- Prevalence per cent of diabetes in '000 worldwide from 2002 to 2012
- Government healthcare expenditure in billion USD worldwide from 2004 to 2014
- Private healthcare expenditure in billion USD worldwide from 2004 to 2014